Literature DB >> 27858709

Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid.

Andrea Gamir-Morralla1,2, Olivia Belbin3,2, Juan Fortea3,2, Daniel Alcolea3,2, Isidro Ferrer4,2, Alberto Lleó3,2, Teresa Iglesias1,2.   

Abstract

Identification of neurodegeneration-monitoring biomarkers would be of great clinical value for Alzheimer's disease (AD) diagnosis. Using N- or C-terminal antibodies, we studied the pro-survival synaptic effector, Kidins220, in the brain and cerebrospinal fluid (CSF) of controls and AD patients. Only the N-terminal antibody showed a positive correlation between Kidins220 and phosphorylated tau in AD brains. Using this antibody, Kidins220 was detected in CSF from AD patients where it positively correlated with CSF phosphorylated tau and tau. This study highlights the potential of Kidins220 as a CSF biomarker in AD.

Entities:  

Keywords:  ARMS; Alzheimer’s disease; Kidins220; amyloid; antibody; biomarkers; calpain; cerebrospinal fluid; excitotoxicity; tau protein

Mesh:

Substances:

Year:  2017        PMID: 27858709     DOI: 10.3233/JAD-160639

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  3 in total

1.  Differential regulation of Kidins220 isoforms in Huntington's disease.

Authors:  Álvaro Sebastián-Serrano; Ana Simón-García; Alicia Belmonte-Alfaro; Julia Pose-Utrilla; María Santos-Galindo; Ana Del Puerto; Lucía García-Guerra; Ivó H Hernández; Giampietro Schiavo; Miguel R Campanero; José J Lucas; Teresa Iglesias
Journal:  Brain Pathol       Date:  2019-07-16       Impact factor: 7.611

2.  Dysregulation of RNA Splicing in Tauopathies.

Authors:  Daniel J Apicco; Cheng Zhang; Brandon Maziuk; Lulu Jiang; Heather I Ballance; Samantha Boudeau; Choong Ung; Hu Li; Benjamin Wolozin
Journal:  Cell Rep       Date:  2019-12-24       Impact factor: 9.423

3.  Kidins220 deficiency causes ventriculomegaly via SNX27-retromer-dependent AQP4 degradation.

Authors:  Ana Del Puerto; Julia Pose-Utrilla; Ana Simón-García; Celia López-Menéndez; Antonio J Jiménez; Eva Porlan; Luis S M Pajuelo; Guillermo Cano-García; Beatriz Martí-Prado; Álvaro Sebastián-Serrano; Marina P Sánchez-Carralero; Fabrizia Cesca; Giampietro Schiavo; Isidro Ferrer; Isabel Fariñas; Miguel R Campanero; Teresa Iglesias
Journal:  Mol Psychiatry       Date:  2021-05-17       Impact factor: 15.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.